Biotech Nocion was in ‘a real pickle,’ then raised $62M in venture capital 03/04/2024
CEO Richard Batycky said the capital would be used to bring Nocion’s lead drug into a Phase 2b study in chronic cough patients and to prepare for a Phase 3 trial. But just last year, Batycky said the future of Nocion wasn’t so certain. ... [...]
School of Science announces 2024 Infinite Expansion Awards 03/04/2024
Nine postdocs and research scientists honored for contributions to the Institute. ... [...]
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 03/04/2024
SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced... ... [...]
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting 03/04/2024
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced it will present new data from its Alzheimer’s disease (AD) portfolio at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place March 5-9 in Lisbon, Portugal and virtually. The... ... [...]
Baxter International to close Acton facility, lay off 59 employees 03/04/2024
Baxter International plans to close its location in Acton only a few years after acquiring it. ... [...]
Arrakis Therapeutics lays off 20% of its workforce 03/04/2024
CEO Michael Gilman explains why the drug developer parted ways with about 20% of its workforce last week. ... [...]
Member Spotlight: Q&A with MCPHS 03/04/2024
Every month, MassBio spotlights a member company and its efforts in advancing the life sciences industry and supporting the patients we serve. In March, we profile the Massachusetts College of Pharmacy and Health Sciences and speak with Carol Stuckey, the dean of the School of Professional Studies. As dean, Carol... ... [...]
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Duchenne Muscular Dystrophy-Associated Cardiomyopathy 03/04/2024
BOSTON, March 4, 2024 /PRNewswire/ -- Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company's phase 2 clinical trial... ... [...]
STAT+: ‘It’s a nightmare’: One of the most common children’s asthma meds is no longer available, leaving families scrambling 03/04/2024
‘It’s a nightmare’: One of the most common children’s asthma meds, GSK's Flovent, is no longer available, leaving families scrambling ... [...]
Merck KGaA bags another molecular glue deal for $16M upfront, this time with C4 03/04/2024
In the latest development in the “highly dynamic” molecular glue space, Merck KGaA has inked a discovery agreement with C4 Therapeutics for two protein degraders against cancer targets. C4 will receive $16 million upfront and is eligible for up to $740 million in milestones and tiered royalties on sales ranging... ... [...]
ALL BCBN NEWS | POST BCBN NEWS
